BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
BioRestorative Therapies (NASDAQ: BRTX) has secured a second clinical site for its Phase 2 trial targeting chronic lumbar disc disease (cLDD). This trial will evaluate the safety and preliminary efficacy of BRTX-100, an autologous stem cell-based therapy, through a randomized double-blind study involving up to 99 patients across 15 sites in the U.S. The principal investigator, Dr. Richard Rauck, will lead the trial at the Center for Clinical Research in North Carolina, enhancing the clinical expertise essential for the trial's success.
- Agreement with a second clinical site for Phase 2 trial targeting chronic lumbar disc disease.
- BRTX-100 therapy could provide a non-surgical treatment alternative for patients.
- Experienced principal investigator, Dr. Richard Rauck, enhancing trial credibility.
- None.
MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has reached an agreement with its second clinical site for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Center for Clinical Research, which is located in North Carolina, is BioRestorative’s second clinical trial contract executed.
BioRestorative’s Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the Company’s autologous investigational stem cell-based therapeutic, BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 sites in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.
“With the signing of our second clinical trial agreement, we are pleased to welcome Dr. Richard Rauck who will be the principal investigator for The Center for Clinical Research,” said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. “Dr. Rauck has extensive clinical experience and brings expertise in the field of cell-based regenerative medicine, which is invaluable for a successful clinical trial.”
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. Pursuant to authorization received from the Food and Drug Administration, we have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission and other public filings. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Email: ir@biorestorative.com
FAQ
What is the purpose of BioRestorative Therapies' Phase 2 clinical trial?
How many patients will be involved in the Phase 2 trial of BRTX-100?
Who is the principal investigator for the clinical trial at the Center for Clinical Research?
How is BRTX-100 administered to patients in the trial?
What is the significance of BioRestorative's clinical trial for investors?
